8-(trifluoromethyl)-1-2-3-4-5-benzopentathiepin-6-amine has been researched along with Alzheimer-Disease* in 2 studies
2 other study(ies) available for 8-(trifluoromethyl)-1-2-3-4-5-benzopentathiepin-6-amine and Alzheimer-Disease
Article | Year |
---|---|
Synthesis of benzopentathiepin analogs and their evaluation as inhibitors of the phosphatase STEP.
Striatal-enriched protein tyrosine phosphatase (STEP) is a brain specific protein tyrosine phosphatase that has been implicated in many neurodegenerative diseases, such as Alzheimer's disease. We recently reported the benzopentathiepin TC-2153 as a potent inhibitor of STEP in vitro, cells and animals. Herein, we report the synthesis and evaluation of TC-2153 analogs in order to define what structural features are important for inhibition and to identify positions tolerant of substitution for further study. The trifluoromethyl substitution is beneficial for inhibitor potency, and the amine is tolerant of acylation, and thus provides a convenient handle for introducing additional functionality such as reporter groups. Topics: Alzheimer Disease; Animals; Benzothiepins; Corpus Striatum; Enzyme Inhibitors; Halogenation; Methylation; Mice; Protein Tyrosine Phosphatases; Rats | 2015 |
Inhibitor of the tyrosine phosphatase STEP reverses cognitive deficits in a mouse model of Alzheimer's disease.
STEP (STriatal-Enriched protein tyrosine Phosphatase) is a neuron-specific phosphatase that regulates N-methyl-D-aspartate receptor (NMDAR) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) trafficking, as well as ERK1/2, p38, Fyn, and Pyk2 activity. STEP is overactive in several neuropsychiatric and neurodegenerative disorders, including Alzheimer's disease (AD). The increase in STEP activity likely disrupts synaptic function and contributes to the cognitive deficits in AD. AD mice lacking STEP have restored levels of glutamate receptors on synaptosomal membranes and improved cognitive function, results that suggest STEP as a novel therapeutic target for AD. Here we describe the first large-scale effort to identify and characterize small-molecule STEP inhibitors. We identified the benzopentathiepin 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (known as TC-2153) as an inhibitor of STEP with an IC50 of 24.6 nM. TC-2153 represents a novel class of PTP inhibitors based upon a cyclic polysulfide pharmacophore that forms a reversible covalent bond with the catalytic cysteine in STEP. In cell-based secondary assays, TC-2153 increased tyrosine phosphorylation of STEP substrates ERK1/2, Pyk2, and GluN2B, and exhibited no toxicity in cortical cultures. Validation and specificity experiments performed in wild-type (WT) and STEP knockout (KO) cortical cells and in vivo in WT and STEP KO mice suggest specificity of inhibitors towards STEP compared to highly homologous tyrosine phosphatases. Furthermore, TC-2153 improved cognitive function in several cognitive tasks in 6- and 12-mo-old triple transgenic AD (3xTg-AD) mice, with no change in beta amyloid and phospho-tau levels. Topics: Alzheimer Disease; Amino Acid Sequence; Animals; Benzothiepins; Catalytic Domain; Cell Death; Cerebral Cortex; Cognition Disorders; Cysteine; Disease Models, Animal; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Male; Mice, Inbred C57BL; Mice, Knockout; Molecular Sequence Data; Neurons; Phosphorylation; Phosphotyrosine; Protein Tyrosine Phosphatases, Non-Receptor; Substrate Specificity | 2014 |